Search results
Results From The WOW.Com Content Network
In children under 15 in first-world countries, the five-year survival rate is greater than 60% or even 90%, depending on the type of leukemia. For infants (those diagnosed under the age of 1), the survival rate is around 40%. [13] In children who are cancer-free five years after diagnosis of acute leukemia, the cancer is unlikely to return. [13]
The five-year survival rate is about 35% in people under 60 years old and 10% in people over 60 years old. [3] Older people whose health is too poor for intensive chemotherapy have a typical survival of five to ten months. [3] It accounts for roughly 1.1% of all cancer cases, and 1.9% of cancer deaths in the United States. [2]
A 2006 follow-up of 553 patients using imatinib (Gleevec) found an overall survival rate of 89% after five years. [33] A 2011 followup of 832 patients using imatinib who achieved a stable cytogenetic response found an overall survival rate of 95.2% after 8 years, which is similar to the rate in the general population.
In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]
The outcome depends on the subtype, with some being curable and treatment prolonging survival in most. [9] The five-year survival rate in the United States for all Hodgkin lymphoma subtypes is 85%, [4] while that for non-Hodgkin lymphomas is 69%. [15] Worldwide, lymphomas developed in 566,000 people in 2012 and caused 305,000 deaths. [16]
[15] [4] In the United States it is the most common cause of cancer and death from cancer among children. [2] Acute lymphoblastic leukemia is notable for being the first disseminated cancer to be cured. [16] Survival for children increased from under 10% in the 1960s to 90% in 2015. [2] Survival rates remain lower for babies (50%) [17] and ...
MGUS is a relatively stable condition afflicting 3% of people aged 50 and 5% of people aged 70; it progresses to multiple myeloma at a rate of 0.5–1% cases per year; smoldering multiple myeloma does so at a rate of 10% per year for the first 5 years, but then falls off sharply to 3% per year for the next 5 years and thereafter to 1% per year.
The 5-year event free survival, disease-free survival, and overall survival rate in the phase 3 clinical study in DS-AMKL were 79, 89, 84 percent, respectively. [13] Other studies that use a treatment regimen similar to that used in the phase 3 clinical study report overall survival rates of ~80% [7] and long-term survivals of 74-91%. [9]